| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 08/01/2013 | WO2013110680A1 Integrin antagonist conjugates for targeted delivery to cells expressing vla-4 |
| 08/01/2013 | WO2013110679A1 Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 |
| 08/01/2013 | WO2013110590A1 Substituted phenylimidazopyrazoles and use thereof |
| 08/01/2013 | WO2013110585A1 5, 8 -dihydro- 6h- pyrazolo [3, 4 -h] quinazolines as igf-lr/lr inhibitors |
| 08/01/2013 | WO2013110578A1 Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |
| 08/01/2013 | WO2013110309A1 Triazolo[4,5-d]pyrimidine derivatives |
| 08/01/2013 | WO2013110135A1 Heterocyclic compounds and methods for their use |
| 08/01/2013 | WO2013110134A1 Heterocyclic compounds and methods for their use |
| 08/01/2013 | WO2013110120A1 Peptide agents for cancer therapy |
| 08/01/2013 | WO2013075105A3 Tcl1 peptides for immunotherapy |
| 08/01/2013 | WO2012111016A8 2-anilino nicotinyl linked 2-amino benzothiazole conjugates and process for the preparation thereof |
| 08/01/2013 | US20130197103 Composition and method for the enhancement of the efficacy of drugs |
| 08/01/2013 | US20130197097 Novel spiroenone and uses thereof |
| 08/01/2013 | US20130197050 Novel lactams and uses thereof |
| 08/01/2013 | US20130197014 Purinone compounds as kinase inhibitors |
| 08/01/2013 | US20130196987 Macrocyclic compounds useful as pharmaceuticals |
| 08/01/2013 | US20130196955 Polymorphisms for predicting disease and treatment outcome |
| 08/01/2013 | US20130196945 Cyclodextrin-based polymers for therapeutics delivery |
| 08/01/2013 | US20130196849 Substituted Cellulose Acetates and Uses Thereof |
| 08/01/2013 | US20130196427 Cancer antigen peptides derived from wt1 |
| 08/01/2013 | US20130196007 Alcohol extract of dehulled adlay seeds for treating breast cancer |
| 08/01/2013 | US20130195847 Treatment with anti-vegf antibodies |
| 08/01/2013 | US20130195771 Gantrez Hydrogel With Dry Tack |
| 08/01/2013 | CA2862492A1 Methods of treatment of cancer |
| 08/01/2013 | CA2862485A1 Peptide agents for cancer therapy |
| 08/01/2013 | CA2861464A1 Proteasome activity modulating compounds |
| 08/01/2013 | CA2861462A1 Proteasome activity enhancing compounds |
| 08/01/2013 | CA2857127A1 Integrin antagonist conjugates for targeted delivery to cells expressing lfa-1 |
| 08/01/2013 | CA2856619A1 Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3 |
| 08/01/2013 | CA2854986A1 Novel galactoside inhibitors of galectins |
| 08/01/2013 | CA2854254A1 Integrin antagonist conjugates for targeted delivery to cells expressing vla-4 |
| 08/01/2013 | CA2854251A1 Chitosan covalently linked with small molecule integrin antagonist for targeted delivery |
| 07/31/2013 | EP2620449A1 Anti-ephrin-b2 antibody and use thereof |
| 07/31/2013 | EP2620443A1 Novel galactoside inhibitors of galectins |
| 07/31/2013 | EP2620433A1 Substituted amide compound |
| 07/31/2013 | EP2620432A2 Diarylhydantoin compounds |
| 07/31/2013 | EP2620151A1 Use of adrenergic beta-3-receptor blockers in cancer treatment |
| 07/31/2013 | EP2620150A2 2-Amido Thiazole Based Inhibitors of ATP-Utilizing Enyzmes |
| 07/31/2013 | EP2620148A1 Antitumoral combination comprising cabazitaxel and cisplatin |
| 07/31/2013 | EP2619331A1 Methods of treating cancer comprising targeting nqo1 |
| 07/31/2013 | EP2619229A2 Multimeric il-15 soluble fusion molecules and methods of making and using same |
| 07/31/2013 | EP2619201A1 Pyrazolopyridines as inhibitors of the kinase lrrk2 |
| 07/31/2013 | EP2619194A1 Fatty acid derivatives of catechins and methods of their use |
| 07/31/2013 | EP2619184A2 Deubiquitinase inhibitors and methods for use of the same |
| 07/31/2013 | EP2619179A1 Matrix metalloproteinase inhibitors |
| 07/31/2013 | EP2619177A1 Matrix metalloproteinase inhibitors |
| 07/31/2013 | EP2618833A2 Breast cancer therapeutics |
| 07/31/2013 | EP2618821A2 Nanostructured gels capable of controlled release of encapsulated agents |
| 07/31/2013 | EP2618817A2 Liposome targeting compounds and related uses |
| 07/31/2013 | EP1476185B1 Antibodies to cd40 |
| 07/31/2013 | CN103228673A Anti-human trop- antibody having antitumor activity in vivo |
| 07/31/2013 | CN103228655A Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| 07/31/2013 | CN103228654A Imidazo [1,2-b] pyridazine and imidazo [4,5-b] pyridine derivatives as JAK inhibitors |
| 07/31/2013 | CN103228651A Compounds useful as inhibitors of atr kinase |
| 07/31/2013 | CN103228648A Crystalline forms of (s)-2-amino-3-(4-(2-amino-6-((r)-1-(4-chloro-2-(3-methyl-1h-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)pyrimidin-4-yl)phenyl) propanoic acid |
| 07/31/2013 | CN103228629A Substituted cyclopentyl -azines as CaSR- active compounds |
| 07/31/2013 | CN103228296A Bendamustine anionic-atioinic cyclopolysaccharide compositions |
| 07/31/2013 | CN103228289A Treating non-hematopoietic cancer with interleukin 6 |
| 07/31/2013 | CN103228284A Methods and compositions for preventing a condition |
| 07/31/2013 | CN103228274A Substituted N-(2-arylamino)aryl sulfonamide-containing combinations |
| 07/31/2013 | CN103224957A Method for producing red blood cell drug containing L-ASPase II by in vitro induction |
| 07/31/2013 | CN103224934A Short interfering ribonucleic acid (siRNA) for oral administration |
| 07/31/2013 | CN103224933A Application of miR-34a gene in non-small cell lung cancer |
| 07/31/2013 | CN103224898A Marine bacillus and its polypeptide with antitumor activity |
| 07/31/2013 | CN103224890A Monascus ruber for high generation of lovastatin and gamma-aminobutyric acid and low generation of pigment, use thereof, and functional Monascus sp. prepared through using Monascus ruber |
| 07/31/2013 | CN103224562A Epitope regions of a thyrotrophin (TSH) receptor, and antibodies thereto |
| 07/31/2013 | CN103224533A Antitumor platinum (II) complex by taking alkyl carboxylate radical as ligand |
| 07/31/2013 | CN103224507A Planar aromatic copper complex and its preparation method and application |
| 07/31/2013 | CN103224500A Annular secondary amino substitution cryptolepine ramification and preparation method thereof and application of annular substitution cryptolepine ramification being used as anti-cancer drug |
| 07/31/2013 | CN103224499A Pheophorbide curcumin ester with photosensitive activity and preparation method and application thereof |
| 07/31/2013 | CN103224497A Inhibitors of protein kinases |
| 07/31/2013 | CN103224496A Tricyclic PI3K and/or mTOR inhibitors |
| 07/31/2013 | CN103224493A Novel oxadiazole derivatives and thiadiazole derivatives having neovascularization inhibitory activity |
| 07/31/2013 | CN103224492A 14-aryl-ether andrographolide derivative and preparation method and application thereof |
| 07/31/2013 | CN103223177A Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene |
| 07/31/2013 | CN103223176A miR-24 and application of inhibitor of miR-24 |
| 07/31/2013 | CN103223174A Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| 07/31/2013 | CN103223171A Porphyrin and uptransition rare earth nanocomposite, preparation method and application thereof |
| 07/31/2013 | CN103223170A Stilbene and uptransition rare earth nanocomposite, preparation method and application thereof |
| 07/31/2013 | CN103223169A Nanocomposite of curcumin and upconversion rare earth, preparation method and application thereof |
| 07/31/2013 | CN103223168A Quinine and uptransition rare earth nanocomposite, preparation method and application thereof |
| 07/31/2013 | CN103223166A Application of human stem cell self-renewal support factor in liver cancer targeting treatment |
| 07/31/2013 | CN103223165A Reducer of immunosuppression by tumor cell and antitumor agent using the same |
| 07/31/2013 | CN103223149A Chinese herb medicine composition for treating lung cancer |
| 07/31/2013 | CN103223144A Traditional Chinese medicine composition for preventing liver cancer |
| 07/31/2013 | CN103223142A Traditional Chinese medicine for treating mastopathy |
| 07/31/2013 | CN103223136A Traditional Chinese medicine extract and its preparation method |
| 07/31/2013 | CN103223135A 中药组合物 Chinese medicine composition |
| 07/31/2013 | CN103223134A 中药组合物 Chinese medicine composition |
| 07/31/2013 | CN103223133A 中药组合物 Chinese medicine composition |
| 07/31/2013 | CN103223126A Traditional Chinese medicinal composition |
| 07/31/2013 | CN103223102A Traditional Chinese medicine formula for effectively treating multiple cancers |
| 07/31/2013 | CN103223093A Bone-nourishing body-building oral liquid and preparing method |
| 07/31/2013 | CN103223085A Chinese medicinal extract |
| 07/31/2013 | CN103223084A 中药组合物 Chinese medicine composition |
| 07/31/2013 | CN103223083A Extract product of traditional Chinese medicine |
| 07/31/2013 | CN103223082A Extract product of traditional Chinese medicine |
| 07/31/2013 | CN103223079A Oral administration lipoma treatment traditional Chinese medicine composition and preparation method thereof |
| 07/31/2013 | CN103223066A Chinese medicinal extract |
| 07/31/2013 | CN103223065A Chinese medicinal extract |